Literature DB >> 10476792

Specific aqueous humor factors induce activation of regulatory T cells.

T Nishida1, A W Taylor.   

Abstract

PURPOSE: To examine the possibility that aqueous humor-induced regulatory T cells could function in vivo, these T cells were examined for their ability to suppress adoptive transfer of delayed-type hypersensitivity (DTH). To begin to understand the mechanisms by which aqueous humor induces activation of regulatory T cells, alpha-melanocyte stimulating hormone (MSH) and transforming growth factor (TGF)-beta2 were examined for ability to induce regulatory T cells.
METHODS: Primed T cells were treated with aqueous humor and assayed for regulatory activity by injecting them intravenously along with DTH-mediating T cells into syngeneic mice. Antigen-pulsed antigen-presenting cells (APCs) were injected into the pinna of the mouse ear, and swelling was measured 24 hours later. Primed T cells were also activated in vitro in the presence of alpha-MSH, TGF-beta1, or TGF-beta2 and were assayed for proliferation and TGF-beta production along with suppressing DTH.
RESULTS: Aqueous humor-treated T cells suppressed inflammation mediated by DTH T cells. Maximum regulatory T cell activity was induced when primed T cells were activated in vitro in the presence of alpha-MSH followed 4 hours later with active TGF-beta2. Such T cells proliferated, produced TGF-beta, and suppressed DTH, suggesting that alpha-MSH and TGF-beta2 induce activation of regulatory T cells. No regulatory T cell activity could be induced in the presence of TGF-beta1.
CONCLUSIONS: The ocular microenvironment constitutively produces immunoregulatory factors that suppress the induction of inflammatory activity and promotes regulatory T cell activity. Such regulatory T cells can further contribute to maintaining the normal immunosuppressive ocular microenvironment through their ability to suppress activation of other inflammatory T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10476792

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  28 in total

1.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

Review 2.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

4.  Alpha-MSH regulates protein ubiquitination in T cells.

Authors:  D J Biros; K Namba; A W Taylor
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2006-05-30       Impact factor: 1.770

Review 5.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

Review 6.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 7.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

8.  Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

Authors:  D J Lee; D J Biros; A W Taylor
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

9.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

10.  The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy.

Authors:  Andrew W Taylor; Nobuyoshi Kitaichi
Journal:  Brain Behav Immun       Date:  2008-01-02       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.